Stomach cancer is a type of cancer that develops in the lining of the stomach. Also, known as Gastric cancer, it affects the elderly more than the adult. According to the American Cancer Society, about 6 of every 10 people diagnosed with stomach cancer each year are 65 or older. Also, the lifetime risk of developing stomach cancer is higher in men (about 1 in 101) than in women (about 1 in 155).

A health expert, speaking to a leading media house, emphasized five common symptoms of stomach cancer that should not be ignored:

1. Unexplained weight loss: Losing weight without trying or experiencing an unexplained drop in appetite, which may signal cancer progression.

2. Pain in the upper part of the abdomen: Persistent or occasional pain in the stomach area, often after eating, can become more severe as the condition progresses.

3. Frequent vomiting after meals: Nausea, sometimes accompanied by vomiting, may occur especially after meals and is linked to cancer blocking or irritating the stomach.

4. Vomiting blood, which may appear coffee-colored: This can indicate bleeding in the stomach, often caused by ulcers or tumors, and requires immediate medical attention.

5. Black, tarry stools: This occurs when blood from the stomach is digested and passed through the intestines, signaling potential internal bleeding

There are also other concerning signs that should not be overlooked such as jaundice, unexplained weight loss, early onset of diabetes, dark stools, and loss of appetite. Health experts strongly advise seeking immediate medical attention if you notice any of these symptoms. If you or a loved one experience these signs, it's crucial to visit a physician for a thorough evaluation to rule out serious underlying health conditions.

How Does Stomach Cancer Spread?

Oncologist Dr Pankaj Kumar Pande, Director–Surgical Oncology, Max Super Specialty Hospital, Shalimar Bagh, Delhi explained that this form of cancer spreads through three main pathways: Direct spread, lymphatic spread, and bloodstream.

1. Direct Spread: In its early stages, stomach cancer can invade nearby tissues and grow into the deeper layers of the stomach or spread to surrounding organs such as the oesophagus, liver, pancreas, or intestines.

2. Lymphatic Spread: Cancer cells can travel through the lymphatic system. The most common areas affected are the regional lymph nodes near the stomach, particularly those around the liver and diaphragm.

3. Bloodstream: "Cancer cells can enter the bloodstream and travel to distant parts of the body," which is a common route for stomach cancer to metastasize to distant organs.

He further explained that cancerous cells spread from the original tumour to other parts of the body through a process called Metastasis. The most common sites for the spread are the liver, lymph nodes, peritoneum, lungs, bones, and ovaries.

Amid the scare of hantavirus led by a rare strain that causes human-to-human transmission, the UK government has received supplies of the antiviral drug Favipiravir from Japan to tackle the risk of the rat-borne disease in the country.

The antiviral favipiravir, from the Japanese company Fujifilm, that gained fame during the COVID-19 pandemic, is being considered as an experimental option to treat the deadly hantavirus outbreak linked to the MV Hondius cruise liner. To date, the medication has been tested as an emergency treatment for new or re-emerging flu.

The UK Health Security Agency said that “the supplies of favipiravir would bolster treatment stocks, even though the risk of wider transmission in the UK remained very low”.

The hantavirus outbreak that began on MV Hondius has so far caused three deaths and 11 cases.

There is no specific therapy for hantavirus, which is primarily spread by rodents but can be transmitted between people in rare cases and after prolonged, close contact. Treatment usually focuses on supportive care such as rest and fluids, while some patients may need breathing support.

Favipiravir’s Role In Viral Treatment

In Japan, favipiravir is sold under the brand name Avigan by a unit of Fujifilm as an emergency medication for novel or re-emerging flu.

The drug works by blocking a key enzyme that many viruses need to multiply.

Use of favipiravir in hantavirus would generally be considered experimental or compassionate rather than standard care, and most likely to treat severe infection early on, said Piet Maes, a virologist at the University of Brussels, Reuters News Agency reported.

Maes said evidence so far comes only from lab and animal studies, with no strong human trial data showing the drug works against hantavirus. There is no internationally established clinical protocol recommending its routine use for hantavirus.

What Is Favipiravir?

Favipiravir is a broad-spectrum antiviral medication, most notably produced and marketed in India by Glenmark Pharmaceuticals under the brand name FabiFlu.

First approved in Japan for severe influenza, it became widely recognized for emergency use in the treatment of mild-to-moderate COVID-19 to help rapidly reduce viral load.

How Effective Has Favipiravir Been?

Favipiravir has remained controversial due to several side effects reported during the COVID-19 pandemic.

In 2023, in a rare complication from treatment with the COVID-19 antiviral, the eyes of a six-month-old baby boy from Thailand turned an unusual shade of blue.

According to researchers from Chulabhorn Royal Academy in Bangkok, the boy, who suffered fever and cough lasting one day, was diagnosed with COVID infection.

In a prior investigation, a higher frequency of uric acid elevation in younger patients treated with favipiravir was observed, which could be linked to decreased urine output.

In addition, favipiravir has also been shown to cause fluorescence in human hair and nails. This adverse effect may be due to the drug, its metabolites, or additional tablet components such as titanium dioxide and yellow ferric oxide.

India has created more than 880 million digital health identities under the country’s flagship mission, the Ayushman Bharat Digital Mission, said Union Health Minister JP Nadda today while addressing the 79th World Health Assembly (WHA) in Geneva.

Speaking at the plenary session, Nadda reaffirmed the country’s commitment to universal health coverage, digital health innovation, and global health solidarity.

“Ayushman Bharat Digital Mission is strengthening India’s national digital health ecosystem by creating over 880 million unique digital health identities, which facilitate longitudinal health records and a seamless continuum of care,” he said.

Expanding Universal Health Coverage

He noted that India is accelerating towards universal health coverage by expanding access to quality and affordable healthcare with a “whole-of-government” and “whole-of-society” approach.

The Union Health Minister informed the Assembly that India has established over 1,85,000 Ayushman Arogya Mandirs across the country to provide comprehensive primary healthcare services closer to communities.

The Minister also underlined the scale and impact of Ayushman Bharat Pradhan Mantri Jan Arogya Yojana, the world’s largest public health assurance scheme, covering nearly 600 million beneficiaries, particularly the most vulnerable sections of society.

Also read: 15 Lakh Indian Chemists To Join May 20 Strike; Govt Says Jan Aushadhi, AMRIT Stores To Stay Open

Focus On Pandemic Preparedness And Technology

Further, Nadda emphasized India’s efforts towards pandemic preparedness and resilient public health systems. He stated that the government is continuously strengthening healthcare infrastructure and emergency response capacities to effectively address future public health challenges.

He also highlighted the transformative role of technology in healthcare and stressed the growing role of Artificial Intelligence in healthcare in the country.

The Minister informed delegates that India has recently launched the Strategy for Artificial Intelligence in Healthcare for India. He emphasized that “the future of AI depends on our collective ability to build ethical and human-centric systems.”

Nadda reaffirmed India’s role as the “Pharmacy of the World” by highlighting the country’s leadership in the production of affordable generic medicines and vaccines.

Recalling India’s contribution during the COVID-19 pandemic, he stated that under the Vaccine Maitri initiative, India supplied nearly 300 million vaccine doses to around 100 countries, reflecting the nation’s enduring commitment to global health cooperation and solidarity.

The 79th World Health Assembly

Read More: No Ebola Case in India, Public Risk Low: Govt Steps Up Surveillance at Airports and Seaports

The 79th WHA will be held from May 18 to May 23 in Geneva under the theme “Reshaping global health: a shared responsibility.”

In his opening remarks at the Assembly, the WHO chief Tedros Adhanom Ghebreyesus referred to recent outbreaks of hantavirus and Ebola, as well as challenges including economic crises and climate change, stressing the need to “build a new global health architecture fit for the future.”

Tedros said this year’s Assembly will consider a proposal for a member state-led, WHO-hosted joint process to reform the global health architecture, Xinhua News Agency reported.

The 79th WHA will review over 60 agenda items, including technical issues such as noncommunicable diseases, mental health, universal health coverage, primary health care, and prevention and response to public health emergencies, as well as administrative issues such as financing, implementation, auditing, and oversight of the WHO’s 2026–2027 programme budget.

As the WHO’s highest decision-making body, the annual WHA is usually held in May in Geneva. Its main functions include deciding WHO policies and reviewing and approving the budget program. This year’s Assembly is scheduled to conclude on .

The third recorded outbreak of the rare Bundibugyo strain of Ebola in the Democratic Republic of Congo (DRC) has been declared a Public Health Emergency of International Concern (PHEIC) by the World Health Organization (WHO).

The 17th outbreak of Ebola virus in the Democratic Republic of the Congo has claimed over 130 lives, with more than 513 suspected cases, BBC quoted local officials as saying.

As per the US Centers for Disease Control and Prevention (CDC), there are also two confirmed cases and one death in Uganda.

With the disease spreading to newer regions and both the death toll and case count rising, experts have raised fresh global health concerns, noting that delayed detection may have allowed the virus to spread across multiple regions.

According to health authorities, early tests failed to identify the correct Ebola strain, leading to crucial weeks being lost before containment efforts began.

Bundibugyo Ebola Outbreak: A Look At How It All Began

The first known case was reportedly a healthcare worker in Bunia, DRC, who began experiencing fever, hemorrhaging, vomiting, and intense malaise on April 24. That person later died, according to the WHO.

However, it took another three weeks before health officials officially confirmed that Ebola was spreading.

Also read: Ebola Outbreak: University of Glasgow Researcher Explains Why Bundibugyo Virus Is Concerning

The WHO noted that a critical four-week detection gap between the onset of symptoms in the presumed index case, and the laboratory confirmation of the outbreak on May 14, suggests a low clinical index of suspicion among healthcare providers.

“This is compounded by the presence of co-circulating arboviruses and influenza-like illnesses, masking the initial index of suspicion for Ebola disease and exacerbating community transmission,” the WHO said.

Further, the infection and death of four healthcare workers within four days at Mongbwalu General Referral Hospital underscores critical breaches in infection prevention and control (IPC) protocols. A large number of community deaths have also been reported, potentially associated with unsafe burial practices, the WHO added.

The US CDC stated that the initial samples tested in DRC were negative for the Ebola virus, but by May 15, eight out of 13 samples tested positive, while five were inconclusive.

Using genetic fingerprinting, the illnesses were identified as the Bundibugyo virus, one of the four types of orthoebolaviruses that cause Ebola disease in people.

On May 17, the WHO declared the Ebola outbreak in Central Africa a “public health emergency of international concern.”

This marks the 17th Ebola outbreak in DRC since 1976. The previous outbreak ended in December 2025.

The current outbreak is the third involving the Bundibugyo virus. The strain was first identified during an outbreak in Uganda in 2007, which resulted in 131 cases and 42 deaths.

Another Bundibugyo outbreak was reported in 2012, killing 50 per cent of infected people in Uganda and 34 per cent in DR Congo.

Bundibugyo Ebola OutbreakWhy Delayed Detection Is Concerning

Speaking exclusively to HealthandMe, Professor Emma Thomson, Director of the Centre for Virus Research (Virology) in the School of Infection and Immunity at University of Glasgow, said the initial negative GeneXpert Ebola tests suggest the outbreak may have gone undetected for some time.

“The reports that initial GeneXpert Ebola testing was negative suggest that the outbreak may have gone undetected for some time, with early diagnostic blind spots delaying recognition,” she said.

Notably, Ebola cases have also been identified in Kinshasa and Kampala. According to Professor Emma, the spread to locations “hundreds of kilometers from Ituri province” indicates that the virus had already moved through human mobility networks before full containment measures were in place.

As a result, “the number of cases is going to go up pretty dramatically,” public health expert and Ebola survivor Craig Spencer told Associated Press.

Health experts stated that the outbreak went undetected for weeks because early tests looked for the wrong strain of the virus.

“Because early tests looked for the wrong strain of Ebola, we got false negatives and lost weeks of response time,” Matthew M Kavanagh of Georgetown University told AP. “We are playing catch-up against a very dangerous pathogen.”

Bundibugyo Ebola: No Approved Vaccine Or Treatment

More concerning is the fact that the outbreak is caused by the Bundibugyo strain, a rare form of Ebola for which there are no approved vaccines or specific treatments.

“We do not currently have a proven, licensed, Bundibugyo-virus-specific vaccine available for outbreak control,” Professor Emma told HealthandMe, stressing the need for urgent vaccine research.

She also highlighted the importance of strengthening therapeutics against the Ebola virus.